Article
Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Cancer chemotherapy and pharmacology - 1 Dec 2013
Motoshima Kohei, Nakamura Yoichi, Sano Kazumi, Ikegami Yoji, Ikeda Takaya, Mizoguchi Kosuke, Takemoto Shinnosuke, Fukuda Minoru, Nagashima Seiji, Iida Tetsuya, Tsukamoto Kazuhiro, Kohno Shigeru
Abstract excerpt
BACKGROUND: We conducted a phase II trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and evaluated the relationship between plasma concentration and efficacy of erlotinib. METHODS: Patients who were previously treated but naive to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), with advanced NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.